FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DevicesNipro Renal Solutions USA, Corporation
Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.
High risk -
DevicesMAST Biosurgery USA, Inc.
MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.
High risk -
DevicesEnvoy Medical Inc.
Envoy Medical in Saint Paul, MN was cited for quality system failures in making its Esteem II Implantable Hearing System, including slow complaint investigations and missed cleanroom contamination risks.
High risk -
DrugsAmneal Pharmaceuticals, LLC
FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.
High risk -
BiologicsSkye Biologics Holdings LLC
FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DevicesIntegra LifeSciences Corporation
FDA warned Integra LifeSciences over bacterial toxin test and sterilization failures at three medical device plants.
High risk -
BiologicsSignature Biologics, LLC
FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
High risk -
DevicesIntegra LifeSciences Corporation
FDA warned Integra LifeSciences over collagen-based medical devices made in Boston after an inspection found quality-system failures and endotoxin testing problems.
High risk -
DrugsBaxter Healthcare Corporation
FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.
High risk